 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...112113114115116117118119120121122123124» |
- | lenvatinib / Generic mfg.
Clinical, Journal: Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. (Pubmed Central) - Mar 14, 2018
Here, we describe a case of a 34-year-old female with recurrent, metastatic, RAIR papillary thyroid cancer who, following her second week of lenvatinib treatment, developed significant CAD which resolved following the termination of the TKI therapy. Given the lack of risk factors for the disorder in the patient's history, the known cardiovascular events associated with the drug, previously described cases of arterial dissections linked to VEGF inhibitors, and the temporal relationship between the onset of symptoms and the treatment start date, a causal relationship between the CAD and lenvatinib is suggested.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: KEYNOTE 523: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Feb 22, 2018
P1b, N=6, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Given the lack of risk factors for the disorder in the patient's history, the known cardiovascular events associated with the drug, previously described cases of arterial dissections linked to VEGF inhibitors, and the temporal relationship between the onset of symptoms and the treatment start date, a causal relationship between the CAD and lenvatinib is suggested. Trial primary completion date: Apr 2017 --> Jun 2018 | Trial completion date: May 2018 --> Jun 2018
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) (clinicaltrials.gov) - Feb 13, 2018
P2, N=100, Not yet recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Surgery, Metastases: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 6, 2018
P2, N=25, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2017 --> Jun 2018 | Trial completion date: May 2018 --> Jun 2018 Initiation date: Jan 2018 --> May 2017
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Feb 5, 2018
P1b/2, N=191, Recruiting, Sponsor: Eisai Inc.
Initiation date: Jan 2018 --> May 2017 N=125 --> 191 | Trial primary completion date: Jun 2018 --> Aug 2019 | Trial completion date: Jan 2019 --> Feb 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 1, 2018
P1b, N=26, Recruiting, Sponsor: Eisai Co., Ltd.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, PD(L)-1 Biomarker, Metastases: Lenvatinib Mesylate and Pembrolizumab in Treating Patients With Metastatic or Recurrent Gastric or Gastroesophageal Cancer (clinicaltrials.gov) - Jan 28, 2018
P2, N=29, Recruiting, Sponsor: New York University School of Medicine
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Jan 26, 2018
P1, N=180, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=125 --> 191 | Trial primary completion date: Jun 2018 --> Aug 2019 | Trial completion date: Jan 2019 --> Feb 2020 Trial primary completion date: Apr 2018 --> Mar 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - Jan 17, 2018
P2, N=161, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Apr 2018 --> Mar 2020 Trial primary completion date: Oct 2020 --> Mar 2020
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=22, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Oct 2020 --> Mar 2020 Trial primary completion date: Dec 2017 --> Mar 2018
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial primary completion date, Metastases: TALENT: Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Jan 17, 2018
P2, N=111, Completed, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Trial primary completion date: Dec 2017 --> Mar 2018 Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Dec 2017
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial termination, Trial primary completion date, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jan 16, 2018
P1, N=7, Terminated, Sponsor: Eisai Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Jul 2017 --> Dec 2017 Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2017
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jan 10, 2018
P2, N=13, Not yet recruiting, Sponsor: Yousef Zakharia
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2017 Initiation date: Dec 2017 --> Mar 2018
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial primary completion date, Combination therapy: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Jan 8, 2018
P1/2, N=132, Recruiting, Sponsor: Eisai Inc.
Initiation date: Dec 2017 --> Mar 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2022 --> Jun 2022
- | lenvatinib / Generic mfg.
Clinical, Journal: OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS. (Pubmed Central) - Dec 30, 2017
Lenvatinib has promising efficacy in RAIR-DTC, but toxicities require frequent early interventions. QOL can be maintained on lenvatinib therapy.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Enrollment closed, Trial primary completion date, Metastases: Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer (clinicaltrials.gov) - Dec 15, 2017
P=N/A, N=23, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
QOL can be maintained on lenvatinib therapy. Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2018 --> Nov 2019
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Dec 14, 2017
P3, N=9, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2018 --> Nov 2019 N=735 --> 9
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Dec 12, 2017
P1b/2, N=125, Recruiting, Sponsor: Eisai Inc.
N=735 --> 9 N=250 --> 125
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Dec 6, 2017
P2, N=20, Recruiting, Sponsor: Eisai Inc.
N=250 --> 125 N=306 --> 20
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (clinicaltrials.gov) - Nov 24, 2017
P2, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=306 --> 20 Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Surgery, Metastases: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 17, 2017
P2, N=25, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Initiation date: Sep 2017 --> Jan 2018
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) (clinicaltrials.gov) - Nov 7, 2017
P2, N=76, Active, not recruiting, Sponsor: Eisai Inc.
Initiation date: Sep 2017 --> Jan 2018 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Nov 7, 2017
P2, N=60, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
Recruiting --> Active, not recruiting Initiation date: Apr 2017 --> Dec 2017
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Oct 26, 2017
P2, N=13, Not yet recruiting, Sponsor: Yousef Zakharia
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies (clinicaltrials.gov) - Oct 25, 2017
P2, N=24, Recruiting, Sponsor: New York University School of Medicine
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: IMMUQ: Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (clinicaltrials.gov) - Oct 18, 2017
P2, N=50, Not yet recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial primary completion date, Metastases: A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments (clinicaltrials.gov) - Sep 26, 2017
P2, N=135, Completed, Sponsor: Eisai Inc.
Initiation date: Apr 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Jan 2014
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date: Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Sep 25, 2017
P1, N=25, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Jan 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Jun 2017
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Sep 25, 2017
P2, N=306, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Sep 2017 | Trial primary completion date: Jul 2020 --> Jan 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (clinicaltrials.gov) - Sep 20, 2017
P2, N=30, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: KEYNOTE 524: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 18, 2017
P1b, N=30, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Sep 2017 | Trial primary completion date: Jul 2020 --> Jan 2021 Trial primary completion date: Dec 2018 --> Aug 2018
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Sep 11, 2017
P1b/2, N=250, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Dec 2018 --> Aug 2018 Trial primary completion date: Jun 2017 --> Jun 2018
- | Biomarker, Review, Journal: Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. (Pubmed Central) - Sep 8, 2017
Most recently, several new drugs including nivolumab, cabozantinib, and a combination of lenvatinib and everolimus have demonstrated acceptable toxicity and significantly improved overall survival, but evidence-based guidelines for sequencing of the approved treatment options and treatment selection based on biomarkers are still missing...Several ongoing clinical trials are evaluating sequencing, timing of cytoreductive nephrectomy, combinations of immunotherapies and targeted therapies as well as selection of the best systemic treatment. Personalized treatment based on tumor profiling is one of the brightest spots on the horizon.
- | Retrospective data, Journal: Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. (Pubmed Central) - Aug 16, 2017
Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient)...Conclusion Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Combination therapy: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Aug 9, 2017
P1/2, N=132, Not yet recruiting, Sponsor: Eisai Inc.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial withdrawal, Metastases: Lenvatinib and Capecitabine in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 26, 2017
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients. N=46 --> 0 | Not yet recruiting --> Withdrawn
- | Journal: Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. (Pubmed Central) - Jun 18, 2017
Interestingly, the vandetanib-resistant KIF5B-RET(G810A) mutant displayed gain-of-sensitivity (GOS) to ponatinib and lenvatinib...These results indicate that KIF5B-RET-associated lung tumors are addicted to the fusion oncogene and ponatinib is the most effective inhibitor for targeting KIF5B-RET in lung adenocarcinoma. Moreover, this study finds a novel vandetanib-resistant RET(G810A) mutation and identifies lenvatinib and ponatinib as the secondary drugs to overcome this vandetanib resistance mechanism.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) - Jun 8, 2017
P2, N=33, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Moreover, this study finds a novel vandetanib-resistant RET(G810A) mutation and identifies lenvatinib and ponatinib as the secondary drugs to overcome this vandetanib resistance mechanism. Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Surgery, Metastases: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 7, 2017
P2, N=25, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: HOPE: Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (clinicaltrials.gov) - Jun 2, 2017
P2, N=39, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Not yet recruiting --> Recruiting Initiation date: Jan 2016 --> Apr 2016
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Jun 1, 2017
P2, N=306, Not yet recruiting, Sponsor: Eisai Inc.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 30, 2017
P1, N=22, Active, not recruiting, Sponsor: Eisai Inc.
Initiation date: Jan 2016 --> Apr 2016 Trial primary completion date: Dec 2016 --> Mar 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Phase II Study of Single Agent Lenvatinib (clinicaltrials.gov) - May 30, 2017
P2, N=30, Recruiting, Sponsor: National University Hospital, Singapore
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Surgery, Metastases: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 24, 2017
P2, N=25, Not yet recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2016 --> Mar 2018 Initiation date: Apr 2017 --> Jul 2017
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date: KEYNOTE 523: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - May 19, 2017
P1b, N=6, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Initiation date: Apr 2017 --> Jul 2017 Recruiting --> Active, not recruiting | N=10 --> 6 | Trial primary completion date: May 2018 --> Apr 2017
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Enrollment change, Trial primary completion date: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - May 18, 2017
P2, N=161, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | N=10 --> 6 | Trial primary completion date: May 2018 --> Apr 2017 Active, not recruiting --> Recruiting | N=41 --> 161 | Trial primary completion date: May 2019 --> Oct 2020
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - May 16, 2017
P1, N=210, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting | N=41 --> 161 | Trial primary completion date: May 2019 --> Oct 2020 Trial primary completion date: Apr 2020 --> Apr 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 (clinicaltrials.gov) - May 16, 2017
P2, N=26, Active, not recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Trial primary completion date: Apr 2020 --> Apr 2018 Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone (clinicaltrials.gov) - May 4, 2017
P2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- || Enrollment change, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Apr 18, 2017
P1, N=260, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=70 --> 260